Opinion|Videos|April 7, 2025
A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
Experts discuss an example illustrating the association between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk and explore how this example can inform our understanding of Lp(a) and ASCVD risk on a population level.
Advertisement
Video content above is prompted by the following:
- Dr Wong, can you offer an example illustrating the association between Lp(a) levels and ASCVD risk?
- How might Dr Wong’s example inform how we think about Lp(a) and ASCVD risk on a population level?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
2
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
3
The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5
